Improved Speed to Clinic by Increasing Automation in Cell Line Development

14th November 2017

Category: Cell Line Development

Tags: , ,

By: Dr Christoph Zehe - Lead Scientist, Dr Monika Holeiter - Senior Scientist, Technology Development,

“Speed to Clinic” is a crucial measure for successful drug development. As a leading provider of stable cell lines, Sartorius Stedim Cellca strives to contribute to this goal by increasing the degree of automation in its Cell Line Development (CLD) technology. While maintaining consistently high quality of the recombinant products, we develop an automation strategy More

Sign-up to receive 3 tips on improving
speed to clinic for biosimilars

Sign-up to receive 3 tips on improving
speed to clinic for biosimilars

* you agree to receive emails with tips, news, insights and quizzes.